CG
INSY

Cutler Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Cutler Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,200
Closed -$2K – 5696
2017
Q4 		$2K Sell
6,200
-10,300
-62% -$67.4K ﹤0.01% 4304
2017
Q3 		$4K Sell
16,500
-32,600
-66% -$336K ﹤0.01% 4700
2017
Q2 		$61K Sell
49,100
-36,300
-43% -$430K ﹤0.01% 2307
2017
Q1 		$42K Buy
85,400
+17,000
+25% +$181K ﹤0.01% 2600
2016
Q4 		$36K Buy
68,400
+29,100
+74% +$329K ﹤0.01% 2882
2016
Q3 		$27K Buy
39,300
+33,100
+534% +$503K ﹤0.01% 3142
2016
Q2 		$3K Sell
6,200
-36,300
-85% -$529K ﹤0.01% 5505
2016
Q1 		$39K Buy
42,500
+7,500
+21% +$142K ﹤0.01% 2597
2015
Q4 		$147K Buy
+35,000
New +$970K 0.01% 1438

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Cutler Group's INSY Position: Q2 2018 in Review

Cutler Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 100 shares.

Cutler Group first reported a position in INSY in Q4 2015 and held it in 10 quarters. The position peaked at $126K in Q2 2017. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

  • Cutler Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 100 Insys Therapeutics, Inc. shares in Q2 2018.
  • Cutler Group first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 10 quarters.
  • Cutler Group's Insys Therapeutics, Inc. position peaked at $126K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.